Ctivities Ortif Ca68752f1036 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Company confident of providing requested information over the coming weeks
Phase I/II clinical trial preparation activities to continue in preparation of anticipated IND approval.
MONTREAL, June 4, 2021 /PRNewswire/ -
Ortho or the
Company ), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today announced that it has received a clinical hold letter from the U.S. Food and Drug Administration ( FDA ) related to its Investigational New Drug (IND) application to begin a phase I/II clinical trial for ORTHO-R, its drug/biologic combination product candidate used as an adjunct to standard of care surgery in rotator cuff tear repair. ....

Claude Leduc , Ortho Regenerative Technologies Inc , Drug Administration , Regenerative Technologies , Investigational New Drug , Chief Executive Officer , Platelet Rich Plasma , Bone Marrow Aspirate Concentrate , Looking Statements , Ortho Regenerative Technologies Inc Stock Exchange , Press Release , Ctivities Ortif Ca68752f1036 , கிளாட் லிடக் , எலும்பியல் மீளுருவாக்கம் தொழில்நுட்பங்கள் இன்க் , மீளுருவாக்கம் தொழில்நுட்பங்கள் , தலைமை நிர்வாகி அதிகாரி , பிளேட்லெட் பணக்கார பிளாஸ்மா , பார்க்கிறது அறிக்கைகள் ,